OBSERVATIONS

Association of Type B Insulin Resistance and Type 1 Diabetes Resulting in Ketoacidosis

Type B insulin resistance (IR) is a rare autoimmune disease characterized by the presence of autoantibodies directed against the insulin receptor, resulting in a marked IR inducing hyperglycemia (1,2). We describe here what we believe to be a case of type 1 diabetes and ketoacidosis associated with type B IR syndrome.

A 55-year-old Caucasian European man with mild obesity (BMI 32.4 kg/m²) was diagnosed as having type 2 diabetes. Insulin therapy was introduced after 3 years of oral antidiabetic therapy when weight loss suggested lack of insulin secretion. Four years after diagnosis, he developed a severe metabolic ketoacidosis. Continuous insulin infusion was promptly introduced, but ketones disappeared only after 6 days. Insulin requirement was exceptionally high (up to 5 units/kg/day for a 21.5 kg/m² BMI) despite the use of a continuous subcutaneous insulin infusion associated with metformin. Clinically, there was neither acanthosis nigricans nor lipodystrophy. Antigliutamic acid decarboxylase 65 (anti-GAD) antibodies were positive on two dosages (3,335 and 3,418 cpm). Triglycerides level was 1.35 mM. Serum IGF-1 was 193 ng/mL (normal range, 55–186 ng/mL) and serum adiponectin was 7.4 μg/mL (normal range, 2.5–6 μg/mL). Soluble nuclear antigen-specific antibodies, antineutrophilic cytoplasmic antibodies, antinuclear antibody, anticalcinin antibodies, serum assay for tumoral tracers, HIV, and viral hepatitis serologies were negative. Pelvic thoracoabdominal computed tomography was normal. Breath test, serologies, and research in feces of Helicobacter pylori were negative.

Anti-insulin receptor autoantibodies, evaluated by their ability to compete with insulin for binding to its receptor in Chinese hamster ovary cells overexpressing the insulin receptor (3), were significantly positive. Half-maximal inhibition of insulin binding was observed at a serum dilution of 1:3 and confirmed using two successive samples from the patient.

In addition to the presence of insulin receptor autoantibodies, the major weight loss, the extreme IR, the clinical course of hyperglycemia, the unusual low triglyceride levels, and the paradoxical increase level of IGF-1 and adiponectin are compatible with the usual presentation of type B IR syndrome (2). In particular, although most states of IR are associated with low serum levels of adiponectin, it is not the case for insulin receptoropathies (4).

Systemic lupus erythematosus and other autoimmune features are common in type B IR syndrome (2). Recently, helicobacter pylori infection was reported to be involved in the development of insulin receptor autoantibodies, but it was not present in our patient. Poor glycemic control and weight loss after diabetes diagnosis and positivity of anti-GAD antibodies suggested diagnosis of latent autoimmune diabetes. Although some reports described the presence of insulin receptor autoantibodies in patients with type 1 diabetes, they were not associated with type B IR syndrome and could represent an anti-idiotypic response to anti-insulin autoantibodies (5). Interestingly, our patient did not present with anti-insulin antibodies.

One year later, insulin requirement spontaneously decreased to 0.3 unit/kg/day and Hba1C was 6.8%. At the same time, anti-insulin receptor antibodies dosage became negative, whereas anti-GAD65 antibodies were still highly positive at 1,536 cpm. We suggest that spontaneous disappearance of circulating anti-insulin receptor autoantibodies explained the insulin sensitivity improvement (2).

From the 1Department of Endocrinology, Nutrition and Diabetes, Pitié-Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; 2Pierre et Marie Curie University Paris 06, Paris, France; 3INSERM, UMR_S 938, Saint-Antoine Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France; 4Department of Biochemistry and Hormonology, Tenon Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France.

Corresponding author: Olivier Bourron, olivier.bourron@psl.aphp.fr.

DOI: 10.2337/dc11-1967 © 2012 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.

Acknowledgments—No potential conflicts of interest relevant to this article were reported.

O.B. cared for the patient, contributed to discussion, and wrote the manuscript. C.V. carried out the determination of anti-insulin receptor antibodies, reviewed the manuscript, and contributed to discussion. M.H. cared for the patient and contributed to discussion. E.B.T. cared for the patient. E.C. and M.C.-D. carried out the determination of anti-insulin receptor antibodies. A.H. contributed to discussion and reviewed the manuscript. O.B. is the guarantor of this article.

References

1. Kahn CR, Flier JS, Bar RS, et al. The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in man. N Engl J Med 1976;294:739–745
2. Arioglu E, Andewelt A, Diaco B, Bell M, Tylor SI, Gorden P. Clinical course of the syndrome of autoantibodies to the insulin receptor (type B insulin resistance): a 28-year perspective. Medicine (Baltimore) 2002; 81:87–100
3. Auclair M, Vigouroux C, Desbois-Mouthon C, et al. Antiinsulin receptor autoantibodies induce insulin receptors to constitutively associate with insulin receptor substrate-1 and -2 and cause severe cell resistance to both insulin and insulin-like growth factors 1. J Clin Endocrinol Metab 1999;84:3197–3206
4. Semple RK, Cochran EK, Soos MA, et al. Plasma adiponectin as a marker of insulin receptor dysfunction: clinical utility in severe insulin resistance. Diabetes Care 2008; 31:977–979
5. Shoelson SE, Marshall S, Horikoshi H, Kolterman OG, Rubenstein AH, Olefsky JM. Antiinsulin receptor antibodies in an insulin-dependent diabetic may arise as autoantiidiotypes. J Clin Endocrinol Metab 1986;63:56–61